Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: Results from the REACT study, a retrospective cohort study.

B Fritzsching, M Contoli, C Porsbjerg… - The Lancet Regional …, 2022 - thelancet.com
… The between group differences in asthma prescriptions were mainly driven by SABA and
ICS/long-acting beta2 agonists (LABA) prescriptions (Table 2, Suppl. Table S7, Figure S7). The …

[HTML][HTML] Trends and characteristics of global initiative for chronic obstructive lung disease guidelines-discordant prescribing of triple therapy among patients with …

SP Bhatt, C Blauer-Peterson, EK Buysman… - … Diseases: Journal of …, 2022 - ncbi.nlm.nih.gov
… muscarinic antagonists [LAMAs], long-acting beta2-agonists [LABAs]) as monotherapy or
in … A total of 41.3% of patients had a history of pneumonia or acute bronchitis/bronchiolitis …

Practice update: COPD-chronic obstructive pulmonary disease

D Rigby - AJP: The Australian Journal of Pharmacy, 2020 - search.informit.org
… Short-acting beta2-agonists (SABA) and short-acting muscarinic antagonists (SAMA) are …
Long-acting beta2-agonists (LABA) cause prolonged bronchodilatation with a duration of …

[引用][C] Advancing the knowledge, understanding and management of respiratory exacerbations of bronchiectasis in children

V Goyal - 2019 - espace.library.uq.edu.au
… Combination inhaled corticosteroids and long-acting beta2-agonists for children and
adults with bronchiectasis. The Cochrane database of systematic reviews 2014;6:CD010327. …

COPD--chronic obstructive pulmonary disease.

D Rigby - Australian Journal of Pharmacy, 2020 - search.ebscohost.com
… Short-acting beta2-agonists (SABA) and short-acting muscarinic antagonists (SAMA) are …
Long-acting beta2-agonists (LABA) cause prolonged bronchodilatation with a duration of …

[HTML][HTML] Beta2 receptor agonists and antagonists

NER Abosamak, MH Shahin - StatPearls [Internet], 2023 - ncbi.nlm.nih.gov
… They can also be given intravenously or intramuscularly in severe acute exacerbations of …
Review A benefit-risk assessment of inhaled long-acting beta2-agonists in the management …

Towards rational prescription of common inhaler medication in the multimorbid COPD patient

I Tsiligianni, KJ Hoeines, C Jensen… - … Journal of Chronic …, 2021 - Taylor & Francis
COPD is a chronic disease, typically accompanied by multiple comorbid conditions. The
need to apply several, and sometimes conflicting, disease-specific treatment guidelines, …

A framework for step down or therapeutic re-organization for withdrawal of inhaled corticosteroids in selected patients with COPD: a proposal for COPD management

C Micheletto, F Braido, M Contoli… - … Journal of Chronic …, 2019 - Taylor & Francis
… The most recent Global Initiative for Obstructive Lung Disease (GOLD) guidelines recommend
triple therapy (long-acting beta2 agonists [LABA] + long-acting muscarinic antagonists […

Respiratory cilia as a therapeutic target of phosphodiesterase inhibitors

M Joskova, J Mokry, S Franova - Frontiers in pharmacology, 2020 - frontiersin.org
Mucociliary clearance is an essential airway defense mechanism dependent predominantly
on the proper ciliary function and mucus rheology. The crucial role of cilia is evident in `a …

[引用][C] Antibiotic Stewardship A call for change

AS Pillai